New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
12:39 EDTCGENCompugen jumps after announcing newly discovered proteins
Compugen (CGEN) is rallying after the company announced earlier today that it has extended discovery capabilities to additional immunomodulatory proteins. WHAT'S NOTABLE: Compugen announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the company’s pipeline program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints. The newly discovered proteins have been added to the company’s pipeline program as potential targets for cancer immunotherapy. Dr. Cohen-Dayag, CEO of Compugen, noted "We are of course very proud that in less than four years, we have established a growing position in this field, including a substantial early-stage pipeline of therapeutic product candidates for both oncology and immunology, based largely on our B7/CD28-like protein candidate discoveries. With today’s announcement, we are further broadening our early-stage pipeline with additional immunomodulatory opportunities and again demonstrating the power and flexibility of our predictive discovery capabilities." PRICE ACTION: In afternoon trading, Compugen 's stock rallied 51c, or almost 6%, to $9.39.
News For CGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
07:12 EDTCGENCompugen to focus on ongoing programs during 2016
Company said, "This past year was a year of significant accomplishment for our company with respect to our unique discovery infrastructure and our target pipeline program. Another key achievement was the aggressive advancement of a second immune checkpoint program, CGEN-15029, which is our leading internal immuno-oncology program. Looking ahead, with substantially expanded capabilities and capacity, during 2016 our R&D focus will be on the advancement of these programs, the addition of immuno-oncology programs based on targets now undergoing validation, and further target discovery efforts."
07:10 EDTCGENCompugen reports Q4 EPS (1c), consensus (11c)
Subscribe for More Information
February 1, 2016
07:28 EDTCGENCompugen coverage assumed with an Outperform at Oppenheimer

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use